Pilot Randomized Neo-adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
Phase of Trial: Phase I
Latest Information Update: 22 Feb 2018
At a glance
- Drugs IMA 950 (Primary) ; Poly ICLC (Primary) ; Varlilumab (Primary)
- Indications Astrocytoma; Oligodendroglioma
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 05 Jan 2018 Planned End Date changed from 1 Jan 2019 to 1 Sep 2020.
- 05 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Mar 2020.
- 10 Jun 2017 Biomarkers information updated